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ABSTRACT  
Essential Hypertension (EHTN) has already emerged as a non-communicable 
pandemic with considerable public health challenges. Its prevalence in India 
ranges from 20-40% in urban adults and 12-17% among rural adults which is 
rapidly increasing. The present clinical study was an approach to evaluate the 
efficacy of Punarnava (Boerhaavia diffusa) (BD) capsules in mild EHTN. 60 
patients were randomly selected and divided into two groups. Their blood 
pressure (BP) measurement, serum urea & creatinine, total cholesterol, serum 
Na+ & K+, ECG & X-ray Chest (PA view) were done before and at the end of the 
treatment. Group T was given the trial drug (each capsule containing 250 mg of 
BD extract) in a dose of 2 capsules twice daily with water for six weeks. Group C 
was given the control drug (each tablet containing 12.5 mg of 
Hydrochlorothiazide (HCTZ) in a dose of 1 tablet once daily in the morning with 
water for six weeks. BD was found effective in reducing both systolic & diastolic 
blood pressure with statistical significance & also significantly improved the 
subjective complains in EHTN. Moreover it was well tolerated by most of the 
subjects and did not produce any harmful side effects. 
INTRODUCTION 
 It is true that the modern lifestyle has drastically 
changed the way we live. Record agricultural harvest, 
rapid industrialization & scientific breakthroughs in 
different fields have really enhanced our standards of 
living. New working culture with limited physical 
activity, processed fast foods, passive forms of 
entertainment, almost no leisure, fragmented family life, 
degraded moral, social, spiritual & ethical values are now 
inevitable parts of our faster life which ultimately results 
in dangerous outcomes like physical & mental stress, 
repetitive strain injuries (RSI) and different lifestyle 
related diseases. Hypertension is one such outcomes of 
modern lifestyle. 
 Essential Hypertension has already become the 
most common cardiovascular disease. It is a major risk 
factor for congestive cardiac failure (CCF), ischemic heart 
disease (IHD), chronic renal failure (CRF) and stroke [1-2]. 
As much as 1 billion individuals worldwide are suffering 
from hypertension and approximately 7.1 million deaths 
per year are caused by hypertension. According to the 
World Health Organization (WHO) report, suboptimal BP 
(>115 mmHg of Systolic BP) is responsible for 62 % of 
cerebrovascular disease and 49 % of IHD, with little 
variation by sex. Not only this but also suboptimal BP is 
the number one attributable risk factor for death 
throughout the world [3]. EHTN has emerged as a major 
public health challenge for developing countries like 
India. The prevalence of hypertension in India ranges 
from 20-40% in urban adults and 12-17% among rural 
adults. The number of hypertension cases was 
approximately 118 million in 2000 which will 
dramatically jump to 214 million in 2025 as per 
estimation and will involve nearly equal numbers of men 
and women [4]. 
 Various allopathic drugs are available at present 
to treat hypertension. Though these drugs are effective 
to certain extent in controlling EHTN, they also have 
their own limitation in terms of safety, side effects and 
economy. Therefore the need of the hour is to 
meticulously search for safe & effective alternative 
medications for management of EHTN. Way back in 
1980, WHO has also emphasized the evaluation of the 
effectiveness and safety of plant products in conditions 
where no safe modern drugs are available. The present 
study is a stepping stone in herbal antihypertensive 
research initiatives.  
 Punarnava (Boerhaavia diffusa) is a very popular 
herb in entire Ayurvedic fraternity. Its use as a diuretic to 
cure renal problems is very common and proved beyond 
doubt [5]. However scientific reviewers have assigned 
many other important pharmacological activities like 
stomachic, digestive, anti-spasmodic, hepatoprotective, 
haematinic, anti-asthmatic, anti-inflammatory, anti-
diabetic etc to this medicinal plant [6]. But a recent study 
published during May 2012 in the International Journal 
of Pharmaceutical Science & Research (IJPSR) found 
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Punarnava to be effective in hypertension by Ca 2+ 
channel antagonising effect in experimental models 
without any undue effect on normal blood pressure [7]. 
The results of this study was the encouraging foundation 
for the current clinical study to evaluate the effectiveness 
of Punarnava in mild (Stage – 1) cases of EHTN. 
MATERIALS & METHODS 
 The present study was a single blind, simple, 
randomized, controlled clinical trial. A total of 60 
ambulatory patients were selected from the OPD of 
Gopabandhu Ayurveda Mahavidyalaya & Hospital, Puri, 
Odisha during the period June 2012 to June 2013 and 
randomly allocated into two groups. Group - T contained 
30 subjects and they were treated with the trial drug i.e. 
Boerhaavia diffusa (BD) Capsules. Group - C also 
contained 30 subjects and they were treated with the 
control drug i.e. Hydrochlorothiazide (HCTZ) Tablets. BD 
produces its appreciable effect in 30 days or so[8]. 
Therefore a reasonable treatment period of six weeks 
was fixed for the study. Another six weeks of follow up 
was also done after the active treatment was stopped. 
Patients were evaluated before starting the treatment 
(baseline) and then at an interval of every two weeks. All 
patients were thoroughly examined and their baseline 
BP (both systolic & diastolic) was recorded before 
starting any treatment. Then Laboratory investigations 
were done for every patient as per the protocol 
suggested by CCRAS for antihypertensive trials. All these 
information were maintained in a well designed research 
case sheet. This clinical study was conducted as per the 
Good Clinical Practice (GCP) guidelines and regulatory 
norms of India. The approval of the Institutional Ethical 
Committee (IEC) was obtained before starting the trial. 
Written informed consent was obtained from every 
patient as a prerequisite to be included in the trial. 
Criteria for Inclusion & Exclusion 
 Both newly diagnosed and already diagnosed 
patients of EHTN of duration < 1 year without taking any 
antihypertensive medication for at least one month were 
selected for the study. We included patients of either sex 
in the age group of 35 – 60 years who had their Systolic 
Blood Pressure (SBP) ≥ 140 mmHg & < 160 mmHg with 
Diastolic blood pressure (DBP) ≥ 91 mmHg & < 100 
mmHg. 
 Patients with hypertension due to any secondary 
cause, pregnant and lactating women, women planning 
pregnancy in next six months, patients with diabetes 
mellitus and patients with any complications like 
nephropathy, retinopathy, Chronic Kidney Disease 
(CKD), Congestive Cardiac failure (CCF), Left Ventricular 
Hypertrophy (LVH), Coronary Artery Disease (CAD) etc 
were excluded from the study. 
Drug, Dosage & Duration 
 Punarnava (BD) capsules manufactured by 
Himalaya Drug Company, (Makali, Bangalore, India) were 
used as the trial drug (TD) and was administered to the 
patients in the Trial Group (Group – T). Each capsule 
contained 250 mg of Punarnava extract. It was given 
orally in a dose of 2 capsules twice in a day with water 
for six weeks. 
 Hydrochlorothiazide (HCTZ) tablets of strength 
12.5 mg each, manufactured by Sun Pharmaceuticals 
were used as the standard control drug and was 
administered orally to the patients of control group 
(Group – C) in a dose of 1 tablet once in the morning with 
water for six weeks and a placebo was added in the 
evening to make the trial and control drug similar as far 
as possible. 
Randomization 
 Patients were registered and examined on first 
come first served basis. They were randomized by 
generating two sets of random unique numbers in a 
randomization table with the help of standard computer 
software program. 
Assessment Criteria 
Clinical Parameters 
 In clinical assessment both Systolic & Diastolic 
Blood Pressure (SBP & DBP respectively) were taken as 
objective Parameters. The mean of SBP & the mean of 
DBP of three different readings at approximately the 
same timing on three consecutive days were taken as the 
baseline value before initiating any treatment. 
Subsequently the BP was recorded at the end of every 
two weeks till the completion of the study. But the same 
process as described above to record the baseline BP was 
applied to record the Blood Pressure at the end of 
treatment (i.e. end of 6th. week) and at the end of follow 
up without medication (i.e. end of 12th. week). The BP 
was recorded every time with the same ISI marked 
Sphygmomanometer to minimize instrumental error. 
 Headache, Dizziness and fatigue were 
considered as the subjective clinical parameters of 
assessment as the study included only mild (Stage – 1 as 
per JNC 7 classification) [1] cases of EHTN.  
 Headache Network Canada (HNC) Pain Scale (a 
self reporting tool to measure headache from 0 – 10) was 
used for headache. 
 Modified Borg rating scale for dizziness which 
measures dizziness from 0 – 10 was used for dizziness 
assessment. 
 Assessment of fatigue was done by Visual 
Fatigue Scale (VFS) designed by Oncology Nursing 
Society (ONS) which measures fatigue from 0 – 10. 
Laboratory Investigations 
 Total Cholesterol, Serum Na+, Serum K +, Serum 
Urea, Serum Creatinine were done for every patient 
included in the trial at base line and at the end of the 
treatment (i.e. end of six weeks). 
Reporting of Adverse Events 
 Adverse events if any with any of the patients 
either in trial or control group were recorded in every 
visit and they were compared with their baseline 
symptoms. Any reported adverse event was recorded 
carefully in the research case sheet. 
Statistical Analysis 
 After assembling the different data in a master 
chart in Microsoft Excel Sheet they were analyzed for 
demographic information, any other information closely 
linked to the disease, efficacy of both trial and control 
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drug in subjective and objective parameters and safety 
profile of both the drugs. Frequency, Mean, Standard 
Deviation, Standard Error of Differences, Range were 
calculated to evaluate continuous variables. Count and 
percentage were used to evaluate categorical variables. 
Students Paired t - test was applied to test the 
significance. Data were presented in both tabular & 
graphical form. All statistical calculations were done by 
using Graph Pad software. 
OBSERVATION & RESULTS 
 A total of 52 (27 from Trial Group & 25 from 
Control Group) subjects completed the study after 3 & 5 
dropouts due to different reasons from Trial & Control 
groups respectively.  
Important Demographic Observations 
 Males (63 %) outnumbered Females (37 %) in the 
present study. 
 The study included subjects in the age group of 30 -
60 but maximum subjects fall in the age group of 41 
– 50 (50 %) & subjects in the age group of 31 – 40 
were minimum (23 %). 
 In alignment of the actual socio economic scenario 
of the locality, the sample was also dominated by 
subjects belonging to Lower Middle Class (as per 
Kuppuswamy’s modified scale of Socio Economic 
Classification) [9] segment (48%). 
 Hypertension was found to be well distributed 
across the subjects of different educational levels. 
However the subjects with only a school level 
education (below matriculation) were maximum 
(30 %) followed by Matriculates (27 %), Graduates 
(23 %), Post graduate (10 %), Intermediate (6 %) 
and Illiterate (4 %). 
 The saliency of Service holders was maximum (33 
%) followed by the saliency of house wives (21 %). 
Both these occupation involves aerobic physical 
inactivity which has a direct positive correlation 
with hypertension [10]. 
Observations Related to Risk Factors 
 31 % subjects of the sample were smokers & 33 % 
were chewing tobacco. This finding is in alignment 
of the fact that smoking is a strong independent risk 
factor for cardiovascular diseases including 
hypertension [11] as people who smoke show higher 
ambulatory blood pressure levels than non-
smokers [12]. 
 10 % subjects of the sample were alcohol abusers. 
Epidemiological data show a linear relationship 
between alcohol consumption and hypertension 
prevalence [12]. 
 The average salt (NaCl) intake per subject per day 
was approximately 15 gram which was 2.5 times 
the recommended quantity. There is a strong 
association between salt intake and elevated blood 
pressure [13]. 
 52% of the total subjects were either overweight or 
obese. This must have increased their risk of 
developing hypertension as there is a direct 
association between blood pressure and body 
weight and/or abdominal adiposity [14]. 
 19 % of the subjects gave a positive family history 
of hypertension or other cardiac events. Positive 
family history is a significant risk factor for 
hypertension [15]. 
RESULTS 
Table : 1 Effectiveness of Trial & Control Drug on objective parameters 
 
T : Trial Group, C : Control Group, DF : Degree of Freedom, SED : Standard Error of Differences, SD : Standard Deviation, S: 
Significant, VS : Very Significant, ES : Extremely Significant & NS : Not Significant 
↑
Mean ± SD Mean ± SD ↓
T 27 151.48 ± 5.75 137.33 ± 5.23 ↓ 0.98 26 14.38 < 0.0001 ES
C 25 152.08 ± 5.49 131.44 ± 8.46 ↓ 1.66 24 12.40 < 0.0001 ES
T 27 95.41 ± 2.06 87.11 ± 4.75 ↓ 0.84 26 9.89 < 0.0001 ES
C 25 95.36 ± 1.89 85.68 ± 5.44 ↓ 1.13 24 8.57 < 0.0001 ES
T 27 202.43 ± 20.19 192.97 ± 15.37 ↓ 1.38 26 6.85 < 0.0001 ES
C 25 205.39 ± 26.39 215.06 ± 29.34 ↑ 3.95 24 2.45 0.0220 S
T 27 144.9 ± 4.62 140.02 ± 4.98 ↓ 0.67 26 7.26 < 0.0001 ES
C 25 145.07 ± 4.73 137.1 ± 4.75 ↓ 0.96 24 8.25 < 0.0001 ES
T 27 3.97 ± 0.64 4.71 ± 0.46 ↑ 0.09 26 7.46 < 0.0001 ES
C 25 4.19 ± 0.54 3.38 ± 0.24 ↓ 0.11 24 7.10 < 0.0001 ES
T 27 27.75 ± 5.97 22.99 ± 3.07 ↓ 0.77 26 6.12 < 0.0001 ES
C 25 29.65 ± 6.43 39.04 ± 4.33 ↑ 1.27 24 7.37 < 0.0001 ES
T 27 0.99 ± 0.19 0.97 ± 0.17 ↓ 0.02 26 1.32 0.1993 NS
C 25 1.01 ± 0.19 1.11 ± 0.18 ↑ 0.03 24 3.13 0.0046 VS
Serum                       
Na+ (mmol/L)
Serum                     
K+ (mmol/L)
Serum Urea 
(mg/dl)
Serum 
Creatinine 
(mg/dl)
Before Treatment After Treatment                        
Systolic              
BP                      
(mm of Hg)
Diastolic              
BP                                 
(mm of Hg)
Total 
Cholesterol 
(mg/dl)
Parameter
Gr
ou
p
n SED D.F
t               
Value
p                        
Value
Inf
ere
nce
AYUSHDHARA, 2015;2(6):390-396 
AYUSHDHARA | November - December 2015 | Vol 2 | Issue 6  393 
Table : 2 Effectiveness of Trial & Control Drug on subjective parameters 
 
S: Significant, VS : Very Significant, ES : Extremely Significant & NS : Not Significant 
Table : 3 Variation of Blood Pressure in Trial Group (TG) during Treatment and Post treatment phase 
 
Chart : 1 Variation of Blood Pressure in Trial Group (TG) during Treatment and Post treatment phase 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
↑
Mean ± SD Mean ± SD ↓
T 15 2.87 ± 1.06 0.53 ± 0.64 ↓ 0.21 14 11.06 < 0.0001 ES
C 12 3 ± 0.95 2.17 ± 1.11 ↓ 0.32 11 2.59 0.0251 S
T 7 2.14 ± 1.07 0.29 ± 0.49 ↓ 0.44 6 4.18 0.0013 VS
C 9 1.78 ± 1.79 2.22 ± 1.3 ↑ 0.58 8 0.77 0.4655 NS
T 10 3.1 ± 0.99 0.8 ± 0.63 ↓ 0.37 9 6.17 < 0.0001 ES
C 17 3.5 ± 1.31 2.41 ± 1.28 ↓ 0.49 16 1.84 0.0936 NS
Fatigue
D.F
t           
Value
p                        
Value
In
fe
re
n
ce
Headache
Dizziness
Parameter
G
ro
u
p
n
Before 
Treatment
After     
Treatment                        SED
MEAN ± SD MEAN ± SD
Before Treatment (BT) 151.48 ± 5.75 95.41 ± 2.06
After Treatment (AT @ End of Week 2) 144.07 ± 6.98 91.48 ± 2.64
After Treatment  (AT @ End of Week 4) 140.15 ± 5.84 88.67 ± 3.96
After Treatment (AT @ End of Week 6) 137.33 ± 5.23 87.11 ± 4.75
 1st Follow up after stopping the Control 
Drug (End of Week 8)
141.11 ± 6.23 90.96 ± 4.38
2nd Follow up after stopping the Control 
Drug (End of Week 10)
145.78 ± 6.01 93.11 ± 3.94
3rd Follow up after stopping the Control 
Drug (End of Week 12)
150.96 ± 5.61 95.33 ± 3.64
OBSERVATION OF BLOOD PRESSURE 
(TRIAL GROUP)
SBP DBP
0.00
20.00
40.00
60.00
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Table : 4 Variation of Blood Pressure in Control Group (CG) during Treatment and Post treatment follow up 
phase 
 
Chart : 2 Variation of Blood Pressure in Control Group (CG) during Treatment and Post treatment follow up 
phase 
 
 
 
 
 
 
 
 
 
 
 
 
Table : 4 Incidence of Adverse effects in Trial & Control Group 
 
 Both the Trial and Control group have shown 
statistically significant reduction of systolic and diastolic 
blood pressure. But the control drug has shown better 
results than trial drug.  
 In Trial Group (TG) the mean Systolic BP before 
treatment was 151.48 ± 5.75. It came down to 137.33 ± 
5.23 after 6 weeks of treatment which was extremely 
significant. On the other hand the mean Diastolic BP 
before treatment was 95.41 ± 2.06 which came down to 
87.11 ± 4.75 after 6 weeks of treatment which was also 
found to be extremely significant.  
 In Control Group (CG) the mean Systolic BP 
before treatment was 152.08 ± 5.49. It came down to 
131.44 ± 8.46 after 6 weeks of treatment. The mean 
Diastolic BP before treatment was 95.36 ± 2.06 which 
came down to 85.68 ± 5.44 after 6 weeks of treatment. 
Both the changes were statistically found to be extremely 
significant. 
MEAN ± SD MEAN ± SD
Before Treatment (BT) 152.08 ± 5.49 95.36 ± 1.89
After Treatment (AT @ End of Week 2) 143.36 ± 6.82 91.68 ± 2.63
After Treatment (AT @ End of Week 4) 139.6 ± 5.94 88.32 ± 4.07
After Treatment (AT @ End of Week 6) 131.44 ± 8.46 85.68 ± 5.44
1st Follow up after stopping the  Control 
Drug (End of Week 8)
140.64 ± 6.18 90.64 ± 4.39
2nd Follow up after stopping the Control 
Drug (End of Week 10)
145.84 ± 6.08 93.04 ± 4
3rd Follow up after stopping the Control 
Drug (End of Week 12)
150.08 ± 5.7 94.64 ± 3.09
OBSERVATION OF BLOOD PRESSURE 
(CONTROL GROUP)
SBP DBP
Trial                          
Group
Percentage 
(%)
Control                                            
Group
Percentage 
(%)
1 Muscle Pain Nil Nil 5 20
2 Stomach Pain 1 3 3 12
3 Blurred Vision Nil Nil 1 4
4 Skin Rashes Nil Nil Nil Nil
5 Orthostatic Hypotension 1 3 4 16
6 Hair Fall Nil Nil Nil Nil
7 Anorexia Nil Nil 3 12
8 Diarrhoea Nil Nil Nil Nil
9 Constipation 1 3 3 12
10 Dry Mouth Nil Nil 1 4
11 Excess Thirst Nil Nil 2 8
12 Nausea Nil Nil 1 4
Type of ComplainSl. No
No of Patients Reporting this complain
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 All the patients in both the Trial & Control Group 
were followed up for a similar six weeks period after 
stopping the Trial & Control Drug respectively. During 
these six weeks follow up phase after the completion of 
six weeks treatment most of the patients in both trial & 
control group showed a gradual raise in both systolic and 
diastolic BP. At the end of Six weeks follow up after 
treatment phase the individual SBP & DBP of both Trial & 
Control Group reached almost to their respective 
baseline values before treatment. 
 The Total Cholesterol decreased from 202.43 ± 
20.19 to 192.97 ± 15.37 mg/dl in trial group where as it 
increased from 205.39 ± 26.39 to 215.06 ± 29.34 mg/dl 
in control group. The changes were extremely significant 
& significant in TG & CG respectively. 
 Serum Sodium (Na+) level decreased 
significantly in both groups. It decreased from 144.90 ± 
4.62 to 140.02 ±4.98 mmol/L & from 145.07 ± 4.73 to 
137.10 ± 4.75 mmol/L in trial & control groups 
respectively.  
 Serum Potassium (K +) level increased from 3.97 
± 0.64 to 4.71 ± 0.46 mmol/L in trial group where as it 
decreased from 4.19 ± 0.54 to 3.38 ± 0.24 mmol/L in 
control group. Statistically both the changes were found 
to be extremely significant. 
 Serum urea level decreased from 27.75 ± 5.97 to 
22.99 ± 3.07 mg/dl in trial group where as it increased 
from 29.65 ± 6.43 to 39.04 ± 4.33 mg/dl in control group. 
Both the changes were statistically found to be extremely 
significant. 
 Serum creatinine level decreased insignificantly 
in trial group from 0.99 ± 0.19 to 0.97 ± 0.17 mg/dl. But 
it increased from 1.01 ± 0.19 to 1.11 ± 0.18 mg/dl in 
control group which was statistically found to be very 
significant. 
 Headache was reduced in both trial & control 
group. It significantly reduced from 2.87 ± 1.06 to 0.53 ± 
0.64 in trial group. But it significantly reduced from 3.00 
± 0.95 to 2.17 ± 1.11 in control group. 
 Dizziness was reduced very significantly from 
2.14 ± 1.07 to 0.29 ± 0.49 in trial group. But it increased 
in control group from 1.78 ± 1.79 to 2.22 ± 1.30; however 
this increase in dizziness was statistically not significant. 
Fatigue was reduced in both trial & control group. It 
reduced from 3.10 ± 0.99 to 0.80 ± 0.63 in trial group & 
from 3.50 ± 1.31 to 2.41 ± 1.28 in control group. The 
change was statistically extremely significant in trial 
group but not significant in control group. 
 The effectiveness of the control drug was better 
in reducing both SBP & DBP but effectiveness of the trial 
drug was much better in subjective parameters like 
headache, dizziness & fatigue. 
 Adverse effects like stomach pain, muscle pain, 
constipation, blurring of vision, orthostatic hypotension 
etc were reported more in control group. There was 
almost no adverse effect reported in the trial group for 
the trial drug except one case each from constipation, 
stomach pain & orthostatic hypotension. 
 
DISCUSSION 
 The antihypertensive activity of the trial drug 
Punarnava may be attributed to its Pharmacological 
properties shown by the active ingredients. Punarnava 
contains active principles like Liridodendrin & 
Hypoxanthine which are active antihypertensive agents 
and the former is Ca+2 channel antagonist. It acts as 
diuretic by increasing renal blood flow [16]. It can relax 
the smooth muscles of the arterial wall. This effect seems 
to be due to the presence of boeravinones and the 
involvement of extracellular calcium and/or L-type 
calcium channels. Further, the methanolic root extract of 
B. diffusa also exerts antioxidant and genoprotective 
activity in both chemical and cell based assays. 
Boeravinone G, H and D appear to be the responsible 
active principles for the antioxidant activity, with 
boeravinone G playing a major role.[17] Ayurveda also 
describes Punarnava to be Rasayana. Therefore it can 
help delaying the aging process of arterial wall & prevent 
arteriosclerosis. It also possesses antihyperlipidemic 
property which helps in improving BP control. 
Punarnava contains Potassium Nitrate (KNO3).Being a 
good source of Potassium (K) it increases serum K+ and 
reduces serum Na+ levels which also facilitates BP 
reduction in HTN. [18] 
 So either of the properties like Calcium channel 
blocking, vasodilating, antihyperlipidemic, serum K+ 
increasing, serum Na + reducing, diuretic & antioxidant 
might be involved singly or in synergistic combination to 
produce the antihypertensive effect of Punarnava. 
 The clinical efficacy of both BD & HCTZ were 
almost comparable in reduction of Essential 
Hypertension where as the safety profile of BD was much 
better as it did not show adverse effects like hyperaemia, 
hypercholesterolemia and hypokalemia in contrast to 
HCTZ. 
CONCLUSION 
 In the present study, Punarnava (Boerhaavia 
diffusa) shown promising results in mild cases of 
essential hypertension. It significantly reduced both SBP 
& DBP in most of the subjects. The results were 
comparable to that of the control drug 
(Hydrochlorothiazide). It also extremely significantly 
reduced other symptoms of EHTN like headache, 
dizziness & fatigue which were also much better as 
compared to the control drug. But our sample size was 
not too big to conclude that Punarnava can be 
confidently given as a single drug in all of the cases of 
mild EHTN. 
 More importantly the trial drug Punarnava was 
well tolerated, absolutely safe and free from adverse 
effects unlike the control drug. Therefore it can be used 
continuously for a long duration without any side effects. 
This fulfils an important criterion to be a successful 
antihypertensive drug. 
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